Arla Foods Ingredients and Alchemy Agencies sign new distribution agreement
AARHUS, Denmark, May 27, 2025 (GLOBE NEWSWIRE) -- Arla Foods Ingredients and Alchemy Agencies have announced a new distribution partnership to serve the performance nutrition market in Australia, New Zealand and the Pacific Islands.
Effective immediately, the distribution agreement will primarily focus on Australia and New Zealand (ANZ). It supports Arla Foods Ingredients' strategy to expand sales in Southeast Asia and in ANZ/Oceania, where Alchemy Agencies is a leading distributor of speciality food and beverage ingredients.
The new agreement covers five key brands in Arla Foods Ingredients' range of premium performance nutrition ingredients:
Lacprodan® whey protein isolate, which contains at least 90% protein and offers solutions for ready-to-drink (RTD) sports beverages, gels, powder shakes and protein bars
Capolac®, a milk mineral concentrate rich in highly bioavailable calcium, magnesium and phosphorus, with benefits for muscle function, healthy bones and body composition
MicelPure®, a micellar casein isolate containing 86% native protein and naturally high in calcium for sports nutrition RTD beverages and shakes
Nutrilac® PB-8420, a high-quality whey and milk protein ingredient that ensures soft texture, processability and robustness for the outer mass of sports protein bars
Nutrilac® MFGM, which is rich in high-quality whey protein and the complex lipids present in milk fat globule membrane to support physical performance and strength
The ANZ region has the second highest per capita global spend on sports nutrition products, including bars, drinks and powder shakes, and Australia is the world's third largest sports nutrition market.1
Alexander Leufgen, Head of Asia at Arla Foods Ingredients, said: 'Arla Foods Ingredients is delighted to welcome Alchemy Agencies as a distribution partner. The new agreement for ANZ/Oceania is an excellent fit for our performance nutrition solutions in this dynamic market. Crucially, it will play a key role in supporting our ambitions in Asia and ensuring our focus on customer centricity and service.'
Tristan Molloy, director of Alchemy Agencies, said: 'We are very excited to bring our expertise in gaining sales and creating strong brand value to Arla Foods Ingredients' performance nutrition ingredients in ANZ/Oceania. The new agreement aligns with our expansion plans for our partner and supplier network and strengthens our involvement in the fast-growing sports nutrition market across our key regions.'
For more information contact:Helence Zhanghz@ispiderpr.com
About Arla Foods IngredientsArla Foods Ingredients is a global leader in improving premium nutrition. Together with our customers, research partners, suppliers, NGOs and others, we discover and deliver documented ingredients and products that can advance lifelong nutrition for the benefit of consumers around the world.
Headquartered in Denmark, Arla Foods Ingredients is a 100% owned subsidiary of Arla Foods.https://www.arlafoodsingredients.com/
LinkedInhttp://www.linkedin.com/company/arla-foods-ingredients
About Alchemy AgenciesAlchemy Agencies is an employee-owned company that has supplied to the Australian, New Zealand and Pacific Islands food and beverage market since 1996. Alchemy is a team of respected industry professionals that are committed to bringing innovative products to the market, and partner with customers and suppliers to develop unique and novel products that offer a point of difference. Technical advice, flexibility and speed of response are key attributes. For more information, visit: alchemyagencies.com
A photo accompanying this announcement is available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/3443bf37-ed82-4199-bb51-58a826027521Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
WaterField's New All-Day Shinjuku Duffel Masters Work, Workout, and Weekends
San Francisco's WaterField Designs introduces the Shinjuku Duffel, featuring dedicated spaces for office gear, clothing, and quick-access essentials. The new carryall combines the professional aesthetic of a briefcase with expanded capacity for fitness and travel, allowing busy professionals to navigate their day with a single, sophisticated bag. SAN FRANCISCO, June 10, 2025 /PRNewswire/ -- San Francisco's WaterField Designs introduces the Shinjuku Duffel, the latest addition to the company's Shinjuku Collection, inspired by the dynamic energy of Tokyo's Shinjuku district. Crafted from ultra-lightweight, water-resistant X-Pac® Canvas or traditional waxed canvas with premium full-grain leather accents, the new compact duffel features three distinct compartments that elegantly organize the essentials of today's digital nomads – from protecting tech devices on daily commutes, to storing gear for lunchtime workouts, to organizing necessities for overnight trips. VIDEO: Tour the Shinjuku Duffel "Many professionals juggle multiple bags throughout their day – a briefcase for work, a gym bag for fitness, and yet another weekender bag for overnight trips," explained company owner Gary Waterfield. "Our Shinjuku Duffel is your ideal everyday, all-day holdall that blends professional aesthetics and flexible functionality for an efficient way to carry just one handsome bag throughout your day." The Shinjuku Duffel's intelligent design solves common carryall frustrations. The bag's layout, structure, and ample organization allow it to hold an overnight's worth of gear without being large and bulky—nothing is swimming around. Its size and quick-access pockets facilitate smooth commuting, so users aren't fishing for their wallet in a large black hole or swinging an unruly bag shaped like a battering ram in crowded spaces. The Shinjuku Duffel's three-zone organization system includes: a dedicated office compartment with padded laptop and tablet sleeves; a spacious main compartment for personal, fitness, or overnight necessities with organization pockets and a collapsible water bottle sleeve; and a full-length zippered front pocket for quick-access items with internal organization and a key tether. This thoughtful separation of work gear from clothing and smaller items caters to commuters, hybrid workers, and frequent travelers. A rear magnetic pocket securely holds passports and other valuables against the body. The main compartment features a full-length zipper that extends down the sides allowing the bag to open wide, while internal gussets keep contents in place. This feature enables users to easily pack, locate, and access items anywhere in the duffel bag, even those at the bottom. A gold, water-resistant liner brightens the interior eliminating the "black hole" effect common to standard duffels. The bright liner also resists stains and wipes clean easily. The Shinjuku Duffel is offered in X-Pac® Canvas – a high-performance textile that combines ultra-lightweight, water-resistant, and highly durable X-Pac® with canvas for a soft touch – making the bag feel light even when fully packed. The duffel is also available in rugged waxed canvas for those preferring a classic, well-traveled aesthetic. Both options feature sumptuous full-grain leather accents. Features: Three custom compartments: A dedicated office section with a padded laptop sleeve with charging cutouts (for up to a 16-inch MacBook Pro), a padded tablet pocket (for up to a 13-inch iPad Pro), and a full-length document pocket. A spacious main compartment with four elevated translucent mesh pockets and a retractable water bottle holder. A three-quarter zipper opens wide and internal gussets keep contents secure. A pleated full-length front quick-access pocket with internal mesh pockets, pen slots, and a key tether. A hidden, magnetic rear pocket holds passports, transit cards, and other quick-access items. Closed-cell foam padding on front, rear, and bottom panels add structure and enhance protection and durability. Gold, easy-clean liner illuminates interior for enhanced visibility. Three carry options ease transport: comfortable leather-wrapped handles, suitcase handle pass-through, and WaterField's removable Supreme Suspension Strap. Available in ultra-light, abrasion and water-resistant X-Pac® Canvas or traditional waxed canvas, each paired with full-grain leather accents, YKK waterproof zippers, and custom metal hardware combine for a look suitable in both formal and casual settings. Handcrafted to exacting standards in San Francisco with a lifetime warranty for defects in materials and workmanship for the product's lifetime. The Shinjuku Duffel is the sixth addition this year to WaterField's Shinjuku Collection of bags, inspired by Tokyo's vibrant trendy neighborhood, each designed to combine mobility and accessibility with sophisticated styling. The new duffel joins WaterField's collection of carryall bags for active professionals. Availability & Pricing: The Shinjuku DuffelPrice: $419Colors and materials: X-Pac® canvas in black or olive green with black full-grain leather accents; navy blue or tan waxed canvas with chocolate full-grain leather accents. Gold ripstop nylon YKK® waterproof zippers, custom metal zipper pulls, rare-earth and weight: 16.5 x 10.5 x 10.5 inches; X-Pac® Canvas 2.4 lbs.; Waxed Canvas 2.85 lbs.; 27 liters. Available now at About WaterField Designs WaterField Designs is an innovative San Francisco designer and manufacturer of bags and cases for tech-savvy consumers who want to stylishly and responsibly transport their technology. WaterField manufactures custom-fitted, high-quality cases and bags for a full range of laptop computers, smartphones, tablets, gaming devices, and other digital gear. All products are manufactured to exacting standards entirely in San Francisco. More information is available at the company website under "Our Story." WaterField Designs, Shinjuku Duffel, Shinjuku Collection, and SFBags are trademarks of WaterField Designs. Other company and product names may be trademarks of their respective owners. Copyright ©2025. All Rights Reserved. View original content to download multimedia: SOURCE WaterField Designs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn
